Trachoma Treatment Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Oral and Topical); By Drug Class; By Region; Segment Forecast, 2024 - 2032

Trachoma Treatment Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Oral and Topical); By Drug Class; By Region; Segment Forecast, 2024 - 2032

The global trachoma treatment market size is expected to reach USD 924.43 million by 2032, according to a new study by Polaris Market Research. The report “Trachoma Treatment Market Share, Size, Trends, Industry Analysis Report, By Route of Administration (Oral and Topical); By Drug Class; By Region; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The rapid increase in the prevalence of trachoma and its proliferation among private and public healthcare organizations to raise awareness about trachoma and its treatment options among the general public are prominent factors driving the market growth. For instance, in January 2024, the number of people living in districts with a high prevalence of active trachoma was estimated at around 116 million in 2023, and over 1.5 million people required surgery for trichiasis.

In addition, a growing number of favorable regulatory policies and incentive programs promoting the development of new trachoma treatments to control the spread of preventable blindness worldwide, further boosting market growth. For instance, in February 2024, The Federal government announced the launch of its new program to eliminate diseases, including trachoma, malaria, filariasis, onchocerciasis, and goehelminthiasis

Furthermore, as trachoma is most prevalent is under-developed or developing economies of MEA and APAC region, thereby the need for significant improvements in healthcare infrastructure is growing and encouraging global healthcare companies to expand their market presence in these emerging and untapped markets. With companies and governments increasingly investing in healthcare infrastructure development and making healthcare services easily accessible to a larger patient population, the demand for effective trachoma treatment options will boost drastically. For instance, according to the International Trade Administration, in January 2024, the Malaysian government continued to strengthen its healthcare sector, increasing the national budget for healthcare to USD 7.9 million compared to USD 7.1 million in 2022.

The emergence of digital health technologies and telemedicine across the globe, which enables the remote diagnosis and treatment of trachoma, is presenting a lucrative opportunity for companies providing trachoma treatment solutions. Also, companies focusing on the development of products for trachoma prevention including hygiene and sanitation solutions and new drugs that are easy to administer and affordable as compared to conventional solutions, are likely to gain a competitive edge in the market.

Trachoma Treatment Market Report Highlights

• Oral segment accounted for a noteworthy share, which is attributed to its characteristics, including systemic coverage, reduced contamination risk, and east administration
• The macrolides segment held a significant share due to its affordability, reduced resistance, easy availability, and shorter treatment time
• North America dominated the global market on account of well-established healthcare infrastructure and rising R&D activities for the development of new solutions
• The key market players include Allergan Inc., Eli Lilly and Company, Bayer AG, Bausch Health Companies, Cipla, Novartis AG, Arbor Pharmaceuticals, and AbbVie

Polaris Market Research has segmented the trachoma treatment market report based on route of administration, drug class, and region:

Trachoma Treatment, Route of Administration Outlook (Revenue - USD Million, 2019 - 2032)

• Oral
• Topical

Trachoma Treatment, Drug Class Outlook (Revenue - USD Million, 2019 - 2032)

• Macrolides
• Tetracycline
• Ophthalmic Anti-Infective
• Sulfonamides

Trachoma Treatment, Regional Outlook (Revenue - USD Million, 2019 - 2032)

• North America

- U.S.

- Canada

• Europe

- Germany

- UK

- France

- Italy

- Spain

- Russia

- Netherlands

- Rest of Europe

• Asia Pacific

- China

- India

- Japan

- South Korea

- Indonesia

- Malaysia

- Australia

- Rest of APAC

• Latin America

- Argentina

- Brazil

- Mexico

- Rest of Latin America

• Middle East & Africa

- UAE

- Saudi Arabia

- Israel

- South Africa

- Rest of MEA